The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

This letter is to inform you that Sagent Pharmaceuticals is recalling Famotidine Injection 200 MG per 50 ML (4 MG/ML) multi-dose vial.

Famotidine Injection is administered intravenously and may be used in adult and pediatric populations. Patients potentially more susceptible to the consequences of intravenous particulate exposure include infants/young children, elderly patients, critically ill patients, and patients with underlying cardiopulmonary disease. These populations may have greater susceptibility to pulmonary microvascular effects of particulate matter.

The out-of-specification particulate matter test result represents a potential health concern because Famotidine Injection is administered intravenously. Particles in the approximate 10–12 µm range may affect the pulmonary microcirculation and, depending on their characteristics, could result in pulmonary microvascular obstruction or related respiratory effects.

Based on the available information, the finding represents a potential but limited health hazard, with no evidence of clinically significant patient harm. To date, Sagent Pharmaceuticals has not received any reports of adverse events related to this recall.

The product lot was distributed nationwide from 12/20/2025 to 04/20/2026.

PRODUCT: Famotidine Injection 200 mg/50 mL (4 mg/mL) multi-dose vial

NDC NUMBER: 25021-756-50

LOT NUMBER: E243A001

EXPIRATION DATE: 02/28/2027